Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Omeros doses first patient in second phase II trial of OMS-824

Feb. 20, 2014

FDA grants accelerated approval to Northera in symptomatic NOH

Feb. 19, 2014

International Stem Cell Corp. and FDA hold pre-IND meeting for Parkinson's disease cell therapy

Feb. 19, 2014

Japanese researchers design new delta opioid receptor agonists

Feb. 19, 2014

Boehringer Ingelheim divulges novel PDE2A inhibitors

Feb. 19, 2014

CNB-001 demonstrates promising neuroprotective activity in vivo

Feb. 19, 2014

Elite Pharmaceuticals reports data from pilot bioequivalence study of ELI-201

Feb. 19, 2014

Prana Biotechnology reports phase II results in Huntington's disease trial

Feb. 19, 2014

Whole-exome sequencing links motor neuron disease and neurodegenerative disorders

Feb. 19, 2014

Achelios Therapeutics to begin phase Ib study of topical ELS-M11 for migraine

Feb. 18, 2014

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...